Authors: Channick, RN Simonneau, G Sitbon, O Robbins, IM Frost, A Tapson, VF Badesch, DB Roux, S Rainisio, M Bodin, F Rubin, LJ

Citation: Rn. Channick et al., Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study, LANCET, 358(9288), 2001, pp. 1119-1123

Authors: Voelkel, MA Wynne, KM Badesch, DB Groves, BM Voelkel, NF

Citation: Ma. Voelkel et al., Hyperuricemia in severe pulmonary hypertension, CHEST, 117(1), 2000, pp. 19-24

Authors: Badesch, DB Tapson, VF McGoon, MD Brundage, BH Rubin, LJ Wigley, FM Rich, S Barst, RJ Barrett, PS Kral, KM Jobsis, MM Loyd, JE Murali, S Frost, A Girgis, R Bourge, RC Ralph, DD Elliott, CG Hill, NS Langleben, D Schilz, RJ McLaughlin, VV Robbins, IM Groves, BM Shapiro, S Medsger, TA Gaine, SP Horn, E Decker, JC Knobil, K

Citation: Db. Badesch et al., Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease - A randomized, controlled trial, ANN INT MED, 132(6), 2000, pp. 425

Authors: Quaife, RA Lynch, D Badesch, DB Voelkel, NF Lowes, BD Robertson, AD Bristow, MR

Citation: Ra. Quaife et al., Right ventricular phenotypic characteristics in subjects with primary pulmonary hypertension or idiopathic dilated cardiomyopathy, J CARD FAIL, 5(1), 1999, pp. 46-54